WELCOME TO PSIVIDA
Focused Therapeutics / Visionary Science
pSivida is a leading provider of miniaturized, sustained-release drug delivery products and is continuing the evolution of these systems.
Our proven proprietary technologies enable us to achieve highly focused long-term delivery of therapeutics. We have developed two of the three products approved by the FDA for the long-term sustained-release delivery of drug to treat chronic eye disease.
Our lead development product, Iluvien ® , delivers fluocinolone acetonide (FA) for the treatment of diabetic macular edema (DME), one of the leading causes of blindness in the developed world. In December 2009, we announced positive data from the 24 month analysis of the Phase III clinical trials. Based on this data, our partner Alimera Sciences is planning to file a New Drug Application with the U.S. Food and Drug Administration in Q2 2010. Iluvien utilizes Medidur™, our third generation miniaturized, sustained-release drug delivery technology.
pSivida, a NASDAQ listed company, is developing products designed to revolutionize treatments in critical areas such as ophthalmology, oncology and cardiology.
